A new program is training nurses across the country to identify the needs of cancer survivors and to help patients and their families achieve the best possible quality of life after treatment.

Dr. Gany works to identify the causes of health disparities in underserved communities, and to develop ways to more effectively deliver care to ethnically diverse populations.

Memorial Sloan-Kettering researchers have discovered a way that cancer cells may be able to exchange information by establishing long bridges between cells called tunneling nanotubes.

Our Annual Report features ten of the year’s most important research and clinical advances, the result of work led by physician-scientists and basic-science investigators.

Memorial Sloan-Kettering has announced its intention to build a new, state-of-the-art outpatient cancer treatment facility on Manhattan’s Upper East Side.

Internationally recognized physician-scientist José Baselga has been named Physician-in-Chief of Memorial Hospital. He joins Memorial Sloan-Kettering from Massachusetts General Hospital.

Enzalutamide, a targeted therapy co-invented by a Memorial Sloan-Kettering investigator, has received FDA approval for the treatment of men with metastatic prostate cancer.